14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
JAGX vs PTN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Jaguar Health, Inc. (JAGX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). JAGX carries a Unified Composite Score of 54.5/100 (HOLD) at $0.39 (N/M Forward P/E, -90.2% operating margin), whereas PTN carries 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin).
Composite vs. Pillar Nuance: While JAGX currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. -90.2% operating margin) and revenue trajectory (-80.1% vs. -58.9% YoY).
Technical & Structure Timing Caution: JAGX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.8); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment71.9% of Rev ($9.5M)
90D Engineering Disclosures0 Published
Investor FAQ JAGX vs PTN Key Questions & Quantitative Answers
As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Jaguar Health, Inc. (JAGX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). JAGX carries a Unified Composite Score of 54.5/100 (HOLD) at $0.39 (N/M Forward P/E, -90.2% operating margin), whereas PTN carries 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin). Composite vs. Pillar Nuance: While JAGX currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. -90.2% operating margin) and revenue trajectory (-80.1% vs. -58.9% YoY). Technical & Structure Timing Caution: JAGX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.8); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
JAGX leads the Growth & Scale pillar: JAGX posts -58.9% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (82.3% gross margin, -90.2% operating margin), compared with PTN at -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), JAGX cumulative revenue shifted +0.0% while PTN shifted -83.3%. In operating R&D and SG&A reinvestment, JAGX deploys N/A (0 90-day corporate R&D disclosures) versus 71.9% of Rev ($9.5M) (0 disclosures) for PTN.
PTN screens cheaper on headline valuation multiples. JAGX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-24.2% FCF margin), whereas PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against JAGX (-548.8% ROE) versus PTN (-877.5% ROE) capital efficiency.
In options market volatility and institutional positioning, JAGX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (30.19β · 228% Vol realized risk). By comparison, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.